JPRN-UMIN000018166
Recruiting
未知
Efficacy and safety in SGLT2 inhibitor for diabetes complicated by non-alcoholic fatty liver disease. - SGLT2 inhibitor for diabetes complicated by NAFLD.
Toranomon Hospital, Department of Hepatology0 sites15 target enrollmentJuly 2, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Type 2 diabetes complicated by non-alcoholic fatty liver disease
- Sponsor
- Toranomon Hospital, Department of Hepatology
- Enrollment
- 15
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Contraindication for SGLT2 inhibitor. Ineligible patients by judgement of family doctor.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Efficacy and safety in SGLT2 inhibitor for non-diabetes complicated by non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.JPRN-UMIN000031041Kobe university school of medicine, Diabetes and Endocrinoplogy30
Completed
Not Applicable
The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetesJPRN-UMIN000016306Tokyo Medical and Dental University50
Recruiting
Not Applicable
Efficacy and safety of SGLT2 inhibitor in patients with diabetic kidneyDiabetic nephropathyJPRN-UMIN000031454ihon University40
Recruiting
Not Applicable
Efficacy and Safety of SGLT2 inhibitors in patients with type 1 diabete.JPRN-UMIN000044317Hokkaido University Hospital200
Recruiting
Not Applicable
Effects of a SGLT2 Inhibitor in type 2 Diabetes Mellitustype 2 Diabetes MellitusJPRN-UMIN000017461ephrology, endocrinology and vascular medicine at Tohoku University Hospital60